



**The Drug Utilization Review Board Reviewed
the Following New Drugs Classes on
December 13, 2016**

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drug class reviews for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL). New drugs and drugs with a recommendation for change in PDL status are highlighted below. The recommendations on all other drugs remained the same as the current PDL status, which is located at <http://dch.georgia.gov/preferred-drug-lists>.

Antivirals, Hepatitis C

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Epclusa (Oral) Tablet* and *Non-Preferred* status with *Prior Authorization* for *Pegasys (Subcutaneous) Syringe/Autoinjector/Solution*.

Parkinson's Disease Psychosis Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Nuplazid (Oral) Tablet*.

Biologic Immunomodulators, Antipsoriatics

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Taltz (Subcutaneous) Syringe/Autoinjector*.